Dostinex and Vaginal bleeding - a phase IV clinical study of FDA data

Summary:

Vaginal bleeding is reported as a side effect among people who take Dostinex (cabergoline), especially for people who are 30-39 old, also take Wellbutrin, and have Acromegaly.

The phase IV clinical study analyzes which people have Vaginal bleeding when taking Dostinex. It is created by eHealthMe based on reports of 2,909 people who have side effects when taking Dostinex from the FDA, and is updated regularly.

What is Dostinex?

Dostinex has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 3,064 Dostinex users. Check the latest studies of Dostinex.

What is Vaginal bleeding?

Vaginal bleeding is found to be associated with 1,128 drugs and 1,539 conditions by eHealthMe. Check the latest studies of Vaginal bleeding.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

2,909 people reported to have side effects when taking Dostinex.
Among them, 20 people (0.69%) have Vaginal bleeding.

Among these 20 people:

What is the age of people who have Vaginal bleeding when taking Dostinex? *

What are other drugs people take besides Dostinex? *

What are other side effects people have besides Vaginal bleeding? *

Anaemia (lack of blood): 8 people, 40.00%
Dyspnea (difficult or laboured breathing): 6 people, 30.00%
Menstruation Irregular: 6 people, 30.00%
Ovarian Cysts (fluid filled sacs of the ovary): 6 people, 30.00%
Fear: 4 people, 20.00%
Flatulence (flatus expelled through the anus): 4 people, 20.00%
Gallstones (stone formation by bile component): 4 people, 20.00%
Constipation: 4 people, 20.00%
Heart Rate Increased: 4 people, 20.00%
High Blood Cholesterol: 4 people, 20.00%

What are the existing conditions these people have? *

Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 7 people, 35.00%
Hormone Level Abnormal: 4 people, 20.00%
Diabetes: 4 people, 20.00%
Constipation: 4 people, 20.00%
Pituitary Tumor Benign: 3 people, 15.00%
Insulin-Like Growth Factor Increased: 3 people, 15.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 10.00%
Urinary Tract Infection: 1 person, 5.00%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 5.00%
Protein C Deficiency: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dostinex and have Vaginal bleeding?

- Check whether Vaginal bleeding is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dostinex:

Dostinex (3,064 reports)

Vaginal bleeding treatments and more:

Vaginal bleeding (49,485 reports)

Browse all side effects of Dostinex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vaginal bleeding:

Vaginal bleeding (1,128 drugs)

Browse all the conditions that are associated with Vaginal bleeding:

Vaginal bleeding (1,539 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Dostinex) and Dostinex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.